Immunovant (IMVT) EBITDA (2018 - 2026)
Immunovant's (IMVT) quarterly EBITDA came in at $161.3 million in Q1 2026, up 42.83% YoY from $112.9 million in Q1 2025, and up 1886.45% on a QoQ basis from $8.1 million in Q4 2025.
Immunovant (IMVT) EBITDA (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of EBITDA data on file, last reported at $161.3 million in Q1 2026.
- Quarterly EBITDA rose 42.83% year-over-year to $161.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.7 million (down 89.53% YoY) and the FY2026 annual result came in at -$193.4 million, changed 0.39% from the prior year.
- EBITDA grew to $161.3 million in Q1 2026, from $8.1 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $377.9 million in Q4 2023 to a low of -$77.8 million in Q3 2025.
- A 5-year average of $66.6 million and a median of $51.7 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA surged 834.06% — and 2024, when it sank 327.23%.
- Tracing IMVT's EBITDA over 5 years: stood at $51.7 million in 2022, then jumped by 630.49% to $377.9 million in 2023, then tumbled by 82.02% to $67.9 million in 2024, then tumbled by 88.05% to $8.1 million in 2025, then surged by 1886.45% to $161.3 million in 2026.
- The last three EBITDA figures came in at $161.3 million (Q1 2026), $8.1 million (Q4 2025), and -$77.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.38 Mn |
| Mar 31, 2026 | 161.30 Mn |
| Dec 31, 2025 | 8.12 Mn |
| Sep 30, 2025 | -77.82 Mn |
| Jun 30, 2025 | -45.89 Mn |
| Mar 31, 2025 | 112.93 Mn |
| Dec 31, 2024 | 67.93 Mn |
| Sep 30, 2024 | 126.04 Mn |
| Jun 30, 2024 | 129.69 Mn |
| Mar 31, 2024 | -71.72 Mn |
| Dec 31, 2023 | 377.91 Mn |
| Sep 30, 2023 | 332.87 Mn |
| Jun 30, 2023 | 60.33 Mn |
| Mar 31, 2023 | 31.57 Mn |
| Dec 31, 2022 | 51.73 Mn |
| Sep 30, 2022 | -45.35 Mn |
| Jun 30, 2022 | -40.01 Mn |
| Mar 31, 2022 | -46.96 Mn |
| Dec 31, 2021 | -39.75 Mn |
| Sep 30, 2021 | -35.42 Mn |